Kamal Adawi, M.S., MBA, serves as Chief Financial Officer and Treasurer at Fate Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and immune disorders. In this pivotal role, Adawi oversees all financial operations, including strategic planning, capital raising, investor relations, and treasury management. He plays a key role in supporting the company's pipeline advancement through innovative financing strategies and ensuring fiscal discipline amid rapid growth in the competitive biotech landscape. With over 20 years of experience in finance and biotechnology, Adawi brings a proven track record of driving financial success in high-growth environments. Prior to joining Fate Therapeutics, he held senior finance positions at leading biotech firms, including Vice President of Finance at a prominent cell therapy company where he orchestrated multiple equity financings totaling over $500 million and navigated complex partnerships with global pharmaceutical giants. Earlier in his career, Adawi worked in investment banking at J.P. Morgan, specializing in healthcare mergers and acquisitions, and earned his MBA from the Wharton School of the University of Pennsylvania, complemented by an M.S. in Financial Engineering from Columbia University. Adawi's achievements include leading successful initial public offerings, optimizing capital structures to extend cash runways during pivotal clinical trial phases, and implementing cost-efficiency programs that enhanced operational margins. At Fate Therapeutics, he has been instrumental in securing non-dilutive funding from government grants and strategic alliances, positioning the company for long-term sustainability and breakthrough innovations in off-the-shelf cell therapies.